Clinical Trials
4 trialsNCT03516279 2026-04-03
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT00895297 2011-12-07
Dasatinib
European Society for Blood and Marrow Transplantation
Phase 2 Terminated